Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation

Study acronym: CHIPS
StatusUnknown
PhasePhase 4
Started

Record status This record was last updated September 19, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Dongying Zhang
3 trials monitored
See all monitored trials
Heart Disease
8,814 trials monitored
See 428 trials at risk
Heart Failure
2,000 trials monitored
See 115 trials at risk
The main purpose of the CHIPS trial is to evaluate the efficacy and safety of colchicine in heart failure with preserved ejection fraction (HFpEF) patients with inflammation, including the effects of colchicine on circulating inflammatory markers, cardiac structure, cardiac function, clinical symptoms and exercise capacity in HFpEF patients.
Trial Details
NCT Number NCT06604611
Lead Sponsor Dongying Zhang
Collaborators: National Natural Science Foundation of China
Conditions
(from sponsor)		 Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Inflammation, Inflammation, Colchicine
Related terms Heart Failure, Inflammation
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov